Physician profile
Scott Geller
NPI 1033661368
$4,334.80
in general payments reported to CMS, 2019-2025
14 companies · $876 in 2025
The $876 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $17.87 · 2024: $3,326 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,763 · Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,762.50 |
| Food and Beverage | $1,440.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,193.72 | 2024-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $346.91 | 2024-2025 | Tremfya |
| Abbvie INC. | $232.10 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $115.64 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $114.10 | 2021 | |
| Madrigal Pharmaceuticals | $90.29 | 2025 | Rezdiffra |
| Pfizer INC. | $57.46 | 2025 | |
| Amgen INC. | $40.26 | 2025 | Uplizna |
| Genzyme Corporation | $29.33 | 2025 | |
| Novo Nordisk INC | $28.23 | 2025 | Wegovy |
| Lilly USA, LLC | $27.24 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $25.34 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.00 | 2025 | Xifaxan |
| Ardelyx, INC. | $13.18 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.